Last reviewed · How we verify
Neostigmine+Glycopyrronium
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrronium blocks muscarinic receptors to counteract cholinergic side effects.
Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrronium blocks muscarinic receptors to counteract cholinergic side effects. Used for Myasthenia gravis, Reversal of neuromuscular blockade.
At a glance
| Generic name | Neostigmine+Glycopyrronium |
|---|---|
| Also known as | Neostigmine |
| Sponsor | Pusan National University Yangsan Hospital |
| Drug class | Acetylcholinesterase inhibitor + Anticholinergic agent |
| Target | Acetylcholinesterase; Muscarinic acetylcholine receptors |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Neostigmine is a reversible acetylcholinesterase inhibitor that increases acetylcholine concentration at the neuromuscular junction and in the central nervous system. Glycopyrronium is an anticholinergic agent added to this combination to prevent excessive parasympathomimetic effects (salivation, bronchospasm, bradycardia) that would otherwise result from neostigmine monotherapy. This combination is used to enhance neuromuscular transmission while maintaining tolerability.
Approved indications
- Myasthenia gravis
- Reversal of neuromuscular blockade
Common side effects
- Dry mouth
- Blurred vision
- Tachycardia
- Urinary retention
- Muscle weakness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neostigmine+Glycopyrronium CI brief — competitive landscape report
- Neostigmine+Glycopyrronium updates RSS · CI watch RSS
- Pusan National University Yangsan Hospital portfolio CI